License deal for early-stage breast cancer drug Nerlynx in South East Asia
The USA’s Puma Biotechnology (Nasdaq: PBYI) has entered into an exclusive agreement under which Specialised Therapeutics Asia will commercialize Nerlynx (neratinib) throughout South East Asia, beginning with Australia, Singapore, Malaysia, Brunei and New Zealand.
Nerlynx was approved by the US Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, making it the first drug to be approved for this specific indication. However, it has not been approved for commercialization in any other countries. In the USA, Nerlynx reportedly costs around $12,000 for a month’s supply.
Currently, Singapore-headquartered Specialised Therapeutics markets US biotech major (Nasdaq: CELG) Celgene’s Abraxane (nab-paclitaxel) and other oncology products in these countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze